| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Galloylpaeoniflorin targets multiple pathways involved in inflammation and oxidative stress; it modulates NF-κB signaling, inhibits pro-inflammatory cytokine production, and activates Nrf2-mediated antioxidant responses; it also interacts with various enzymes including cyclooxygenase and lipoxygenase.
|
|---|---|
| ln Vitro |
In vitro, Galloylpaeoniflorin exhibits antioxidant activity by scavenging free radicals and reducing oxidative stress in cultured cells; it inhibits the production of TNF-α, IL-1β, and IL-6 in LPS-stimulated macrophages; it also protects neuronal cells against glutamate-induced excitotoxicity.
|
| ln Vivo |
In vivo, Galloylpaeoniflorin demonstrates anti-inflammatory and neuroprotective effects in animal models; it reduces paw edema in carrageenan-induced inflammation models, attenuates cognitive impairment in mouse models of Alzheimer's disease, and protects against liver injury in models of hepatotoxicity.
|
| Enzyme Assay |
Non-cellular antioxidant assay: Galloylpaeoniflorin is evaluated for free radical scavenging activity using DPPH (2,2-diphenyl-1-picrylhydrazyl) or ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) assays; the compound is incubated with the radical solution and the decrease in absorbance is measured spectrophotometrically; IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays: Cells (e.g., RAW 264.7 macrophages, SH-SY5Y neuronal cells, or HepG2 hepatocytes) are treated with Galloylpaeoniflorin prior to stimulation with LPS, H₂O₂, or other stressors; inflammatory markers (TNF-α, IL-6, iNOS, COX-2) are measured by ELISA or qRT-PCR; oxidative stress markers (ROS, MDA, GSH) are quantified; cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal experiments: Galloylpaeoniflorin is administered to mice or rats via oral gavage or intraperitoneal injection in models of inflammation (carrageenan-induced paw edema), neuroinflammation (LPS-induced), or hepatotoxicity (CCl₄-induced); tissue histology, inflammatory cytokine levels, oxidative stress markers, and behavioral outcomes are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Galloylpaeoniflorin is a glycoside with moderate oral bioavailability; it is metabolized by intestinal flora and hepatic enzymes; its plasma half-life is relatively short; tissue distribution studies show accumulation in the liver and kidneys.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Galloylpaeoniflorin is generally well-tolerated at pharmacological doses in preclinical studies; no significant acute toxicity has been reported; high doses may cause mild gastrointestinal discomfort; it is considered a safe natural compound.
|
| References |
|
| Additional Infomation |
Reports indicate that [(2R,3S,4S,5R,6S)-6-[[(1R,2S,3R,5R,6R,8S)-2-(benzoyloxymethyl)-6-hydroxy-8-methyl-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decane-3-yl]oxy]-3,4,5-trihydroxyoxacyclohexane-2-yl]methyl 3,4,5-trihydroxybenzoate has been found in peony (Paeonia tenuifolia) and Phellodendron amurense, and related data are available.
Other information: Galloylpaeoniflorin is a bioactive constituent of Paeonia radix, a traditional Chinese medicine used for its anti-inflammatory and analgesic properties; it is under investigation for its potential in treating neurodegenerative diseases, inflammatory disorders, and metabolic syndrome. |
| Molecular Formula |
C30H32O15
|
|---|---|
| Molecular Weight |
632.57
|
| Exact Mass |
632.174
|
| CAS # |
122965-41-7
|
| PubChem CID |
101604718
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
887.7±65.0 °C at 760 mmHg
|
| Flash Point |
290.8±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.735
|
| LogP |
4.89
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
45
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)O)O
|
| InChi Key |
KLFIUQCKSSAFFU-QHOIGUMUSA-N
|
| InChi Code |
InChI=1S/C30H32O15/c1-27-11-29(39)18-9-30(27,28(18,26(44-27)45-29)12-41-23(37)13-5-3-2-4-6-13)43-25-22(36)21(35)20(34)17(42-25)10-40-24(38)14-7-15(31)19(33)16(32)8-14/h2-8,17-18,20-22,25-26,31-36,39H,9-12H2,1H3/t17-,18-,20-,21+,22-,25+,26-,27+,28+,29-,30+/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-6-[[(1R,2S,3R,5R,6R,8S)-2-(benzoyloxymethyl)-6-hydroxy-8-methyl-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~158.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5809 mL | 7.9043 mL | 15.8085 mL | |
| 5 mM | 0.3162 mL | 1.5809 mL | 3.1617 mL | |
| 10 mM | 0.1581 mL | 0.7904 mL | 1.5809 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
